Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02090283 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
A Phase 2 study, sponsored by Scioderm.
- Terminated
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02090283 is a Phase 2 study that was terminated before completion, run by Scioderm. The registered enrollment target is 42 participants.
The verdict
NCT02090283, a Phase 2 study, was terminated before completion, sponsored by Scioderm.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the continued safety of topical use of SD-101 cream (6%) in participants with Epidermolysis Bullosa (EB). Funding Source: FDA Office of Orphan Products Development
Interventions
- DRUG SD-101 dermal cream (6%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-03-26 |
| Est. Completion | 2018-09-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02090283
The ClinicalTrials.gov registry entry for NCT02090283 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scioderm, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SD-101 dermal cream (6%) is the first listed.
NCT02090283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02090283 about?
NCT02090283 is a clinical study titled "Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa". The purpose of this study was to assess the continued safety of topical use of SD-101 cream (6%) in participants with Epidermolysis Bullosa (EB). Funding Source: FDA Office of Orphan Products Development
What is the current status of trial NCT02090283?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2014-03-26. Estimated completion is 2018-09-14.
What interventions are being tested in trial NCT02090283?
The interventions under investigation include: SD-101 dermal cream (6%) (DRUG).
Who is sponsoring clinical trial NCT02090283?
This trial is sponsored by Scioderm, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.